Effect of allergen-specific immunotherapy on recombinant human interleukin 3-mediated amplification of allergen-induced basophil histamine release

Allergy and Asthma Proceedings

Volumn 26, Issue 6, 2005, Pages 456-462

  Kowal, Krzysztof ^a   Nolte, Hendrik ^b   Skov, Per Stahl ^b   DuBuske, Lawrence M ^c,d  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Mental Health Center Glostrup   (Denmark)

^c Immunology Research Institute of New England   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; INTERLEUKIN 3; INTERLEUKIN 5; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BASOPHIL; CHILD; DESENSITIZATION; DRUG EFFECT; FEMALE; HISTAMINE RELEASE; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; PERENNIAL RHINITIS;

ADOLESCENT; ADULT; ALLERGENS; BASOPHILS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HISTAMINE RELEASE; HUMANS; INTERLEUKIN-3; INTERLEUKIN-5; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 30844446932     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Durham SR, Walker SM, Varga EM, et al. Long term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
2. Jacobsen L, Nuchel Petersen B, Wihl JA, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 52:914-920, 1997.
3. Ewan PW, Alexander MM, Snape C, et al. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 18:501, 1988.
4. Ross RN, Nelson HS, and Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: An analysis of randomized, prospective, single- or double- blind, placebo-controlled studies. Clin Ther 22:342-350, 2000.
5. Lichtenstein LM, Norman PS, and Winkenwerder WL. Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med 44:514-524, 1968.
6. Lichtenstein LM, Norman PS, Winkenwerder WL, et al. In vitro studies of human ragweed allergy: Changes in cellular and humoral activity associated with specific desensitization. J Clin Invest 45:1126-1136, 1966.
7. Pruzansky JJ, and Patterson R. Histamine release from leukocytes of hypersensitive individuals II. Reduced sensitivity of leukocytes after injection therapy J Allergy 39:44-50, 1967.
8. Chyrek-Borowska S, Kuczewska B, Rogalewska A, and Hofman J. Immunologic hisatmine release from isolated human basophils during specific immunotherapy. Agents Actions 18:176-177, 1986.
9. Norman PS, Lichtenstein LM, and Ishizaka K. Diagnostic tests in ragweed hay fever. A comparison of direct skin tests, IgE antibody measurements, basophil histamine release. J Allergy Clin Immunol 52:210-224, 1973.
10. Lichtenstein LM, and Osler AG. Studies on the mechanisms of hypersensitivity phenomena. IX. Histamine release from human leukocytes by ragweed pollen antigen. J Exp Med 120:507-530, 1964.
11. Siraganian RP. Automated histamine analysis for in vitro allergy testing. II. Correlation of skin test results with in vitro whole blood histamine release in 82 patients. J Allergy Clin Immunol 59:214-222, 1977.
12. MacGlashan DW Jr, and Hubbard WC. Interleukin-3 alters free arachidonic acid generation in C5a-stimulated human basophils. J Immunol 151:6358-6369, 1993.
13. Kurimoto Y, de Weck AL, and Dahinden CA. The effect of interleukin 3 upon IgE-dependent and IgE-independent basophil degranulation and leukotriene generation. Eur J Immunol 21:361-368, 1991.
14. Kuna P, Reddigari SR, Schall TJ, et al. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol 150:1932-1943, 1993.
15. Robinson RA, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-302, 1992.
16. Kay AB, Ying S, Varney V, et al. Messenger RNA expression of the cytokine gene cluster IL-3, IL-4, IL-5. and GM-CSF in allergen-induced late phase cutaneous reactions in atopic subjects. J Exp Med 173:775-783, 1991.
17. Massey W, Friedman B, Kato M, et al. Allergen-induced late phase reaction sites contain IL-3 and GM-CSF activity. J Allergy Clin Immunol 87:207, 1991.
18. Allam M, and Renzi PM. Inhibition of GM-CSFAL-3/IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors. Antisense Nucleic Acid Drug Dev 11:289-300, 2001.
19. Yamada T, Sun Q, Zeibecoglou K, et al. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor a-subunit, and common b-subunit expression by peripheral leukocytes and blood dendritic cells. J Allergy Clin Immunol 101:677-682, 1998.
20. Schleimer RP, Derse CP, Friedman B, et al. Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J Immunol 143:1310-1317, 1989.
21. Brunner T, Heusser CH, and Dahinden CA. Human peripheral blood basophils primed by interleukin-3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 177:605-611, 1993.
22. Yamaguchi H, Hirai K, Ohta K, et al. Culturing in the presence of IL-3 converts anti-IgE nonresponding basophils into responding basophils. J Allergy Clin Immunol 97:1279-1287, 1996.
23. Nolte H, Storm K, and Schiotz PO. Diagnostic value of a glass fiber based histamine analysis for allergy testing in children. Allergy 45:213-223, 1990.
24. Miadonna A, Cottini M, Milazzo N, et al. In vivo and ex vivo inhibitory effects of loratadine on histamine release in patients with allergic rhinitis. Allergy 53:1183-1188, 1998.
25. Louis R, Bury T, Corhay JL, and Redermecker M. Effects of acute injection of methylprednisolone in man on immunologic and non-immunologic histamine release from leukocytes and its potentiation by interleukin-3. Clin Exp Allergy 24:60-65, 1993.
26. Kivity S, Onn A, Agami O, and Fireman E. The in vitro and in vivo effect of corticosteroides on basophil releasability in patients with mild and severe bronchial asthma. Clin Exp Allergy 27:909-914, 1997.
27. Kuna P, Alam R, Kuzminska B, et al. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: Results of a double-blind placebo-controlled randomized study. J Allergy Clin Immunol 83:816, 1989.
28. Secrist H, Chelen CJ, Yan W, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178:2123-2130, 1993.
29. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92:644-651, 1993.
30. Miadonna A, Salamaso C, Cottini M, et al. Enhancement of basophil histamine release by interleukin-3: Reduced effect in atopic subjects. Allergy 51:525-531, 1996.
31. Beauvais F, Echasserieau K, Burtin C, and Benvenieste J. Regulation of human basophil activation: The role of Na+ and Ca2+ in IL-3-induced potentiation of IgE-mediated histamine release from human basophils. Clin Exp Immunol 95:191-194, 1994.
32. Brunet C, Bedard PM, Lavoie A, et al. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 89:76-86, 1992.
33. Lie WJ, Van Der Veen MJ, Mul FP, et al. Influence of bronchial allergen challenge on histamine release by human basophils. Clin Exp Allergy 30:882-890, 2000.